| Literature DB >> 26322540 |
F C P Tiago1, B A A Porto1, N S Ribeiro1, L M C Moreira1, R M E Arantes2, A T Vieira3, M M Teixeira3, S V Generoso4, V N Nascimento4, F S Martins1, J R Nicoli1.
Abstract
In the present study, the protective potential of Saccharomyces cerevisiae strain UFMG A-905 was evaluated in a murine model of acute ulcerative colitis (UC). Six groups of Balb/c mice were used: not treated with yeast and not challenged with dextran sulphate sodium (DSS) (control); treated with S. cerevisiae UFMG A-905 (905); treated with the non-probiotic S. cerevisiae W303 (W303); challenged with DSS (DSS); treated with S. cerevisiae UFMG A-905 and challenged with DSS (905 + DSS); and treated with S. cerevisiae W303 and challenged with DSS (W303 + DSS). Seven days after induction of UC, mice were euthanised to remove colon for enzymatic, immunological, and histopathological analysis. In vivo intestinal permeability was also evaluated. An improvement of clinical manifestations of experimental UC was observed only in mice of the 905 + DSS group when compared to animals from DSS and W303 + DSS groups. This observation was confirmed by histological and morphometrical data and determination of myeloperoxidase and eosinophil peroxidase activities, intestinal permeability and some pro-inflammatory cytokines. S. cerevisiae UFMG A-905 showed to be a potential alternative treatment for UC when used in an experimental animal model of the disease.Entities:
Keywords: Saccharomyces cerevisiae; dextran sulphate sodium; inflammatory bowel disease; probiotic; ulcerative colitis
Mesh：
Year: 2015 PMID： 26322540 DOI： 10.3920/BM2015.0018
Source DB: PubMed Journal: Benef Microbes ISSN： 1876-2883 Impact factor: 4.205